Aardvark Therapeutics AARD
NASDAQ AARD
$4.43 +0.53 (+13.59%)
As of: Oct 21, 2026 · 3:26 PM EDT

Aardvark Therapeutics (AARD) EBIT (2024 - 2026)

Updated

Aardvark Therapeutics (AARD) reported EBIT of -$15.08 million for Q2 2026, compared with -$15.85 million a year earlier.

Analysis

Aardvark Therapeutics (AARD) EBIT (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Aardvark Therapeutics' EBIT came in at -$73.96 million; for FY2025, it came in at -$62.73 million.

  • By year, EBIT came in at -$22.79 million in FY2024.
  • The Q2 2026 figure ranks as the highest quarterly EBIT since Q1 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -$22.46 million (Q1 2026), -$18.7 million (Q4 2025) and -$17.7 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,137.85 Bn 1,106.43 Bn 19.71 Bn 11.75 Bn
2 Johnson & Johnson 618.85 Bn 537.37 Bn 17.26 Bn 7.14 Bn
3 AbbVie 503.03 Bn 476.14 Bn 12.70 Bn 6.43 Bn
4 Merck 368.52 Bn 322.90 Bn 12.21 Bn -584.00 Mn
5 Novartis Ag 298.19 Bn 262.18 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn 3.16 Bn
7 Amgen 237.14 Bn 192.53 Bn 7.24 Bn 3.51 Bn
8 Gilead Sciences 191.35 Bn 165.54 Bn 6.22 Bn -10.39 Bn
9 Pfizer 169.80 Bn 116.45 Bn 10.94 Bn 4.27 Bn
10 Aardvark Therapeutics 96.78 Mn 22.88 Mn - -15.08 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.08 Mn
Mar 31, 2026 -22.46 Mn
Dec 31, 2025 -18.70 Mn
Sep 30, 2025 -17.70 Mn
Jun 30, 2025 -15.85 Mn
Mar 31, 2025 -10.47 Mn
Dec 31, 2024 -9.45 Mn
Sep 30, 2024 -5.09 Mn
Jun 30, 2024 -6.07 Mn
Mar 31, 2024 -2.17 Mn
API Access

Aardvark Therapeutics EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=AARD&period=max&api_key=YOUR_API_KEY